How Does TDM-105795 Differ From More Established Hair Loss Ingredients When Included in Experimental or Emerging Treatments?

When evaluating any emerging hair loss compound, the first question is not whether it is exciting, but whether it meaningfully differs from what already exists. TDM-105795 has been presented as a novel topical treatment for androgenetic alopecia, yet novelty alone does not equal clinical relevance. To understand how TDM-105795 differs from established hair loss ingredients, we must examine its proposed biological action, the quality of evidence supporting it, and how this evidence compares to decades of research behind existing therapies. This evaluation matters because hair loss treatments are long-term interventions, often used for years, and early assumptions based on limited trials can mislead both clinicians and patients.

TDM-105795 is an investigational small-molecule compound developed for topical application. A 2025 review describes it as a thyroid-receptor β1 agonist (Kim et al., 2025), meaning it is designed to activate thyroid hormone receptors in a targeted way. Thyroid hormones are known to influence hair follicle cycling, particularly the transition between resting and growth phases. This theoretical basis differentiates TDM-105795 from most approved hair loss drugs, but theory must be weighed against empirical data.

What We Already Know About Established Hair Loss Treatments

To assess whether TDM-105795 is meaningfully different, it is necessary to clarify how established treatments work and why they are considered benchmarks. Minoxidil and finasteride are not considered effective because of marketing claims, but because their mechanisms and outcomes have been repeatedly documented in controlled human studies.

Minoxidil, approved by the U.S. Food and Drug Administration for androgenetic alopecia, is a topical vasodilator originally developed as an antihypertensive drug. Its hair growth effect is associated with prolongation of the anagen phase, the active growth stage of the hair cycle. While its exact molecular mechanism remains incompletely understood, research suggests it enhances follicular cell survival and increases local blood supply, indirectly supporting hair fiber production. Randomized placebo-controlled trials, mostly lasting up to about a year, have shown increased hair counts in both men and women; longer-term data come mainly from uncontrolled follow-up, and discontinuation leads to loss of the gained hair.

Finasteride represents a different therapeutic strategy. It is an oral 5-alpha-reductase inhibitor that reduces conversion of testosterone into dihydrotestosterone, the androgen most strongly associated with follicle miniaturization in genetically susceptible individuals. Finasteride does not stimulate new follicles but slows or partially reverses miniaturization of existing ones. Its effectiveness is supported by large, multi-year clinical trials. Because it acts on hormones throughout the body, it carries label warnings. Since approval, some men have reported sexual problems that continued after they stopped finasteride, and the US, UK and EU product information all describe these reports; how often this happens is not known. The UK regulator (MHRA, May 2026) advises stopping finasteride 1 mg immediately and contacting a doctor if depression or suicidal thoughts develop. Women who are or may be pregnant should not handle crushed or broken tablets.

These treatments form the reference point against which TDM-105795 must be judged, not only in terms of efficacy but also in terms of biological plausibility, safety, and durability of effect.

The Biological Rationale Behind TDM-105795

The distinguishing feature of TDM-105795 is its relationship to thyroid hormone signaling. Thyroid hormones play a role in regulating metabolism and cell differentiation, and their influence on hair follicles has been observed in both clinical endocrinology and experimental dermatology. Hypothyroidism and hyperthyroidism are both associated with hair abnormalities, suggesting that precise modulation of thyroid pathways could theoretically influence hair cycling.

Laboratory research on human scalp follicles in culture found that thyroid hormones prolonged the growth (anagen) phase (van Beek et al., 2008). TDM-105795 is designed to act locally on the scalp, theoretically avoiding the systemic effects seen with oral thyroid hormone manipulation. This localized approach is often cited as a key innovation, but it remains a hypothesis until validated by robust pharmacokinetic and long-term safety data in humans.

What the Human Studies Actually Show

Human evidence for TDM-105795 remains limited. The only controlled data are from one 16-week Phase 2 trial in 71 men with mild to moderate androgenetic alopecia (NCT05802173), after two small Phase 1 safety studies in men. In that trial, TDM-105795 was applied topically at 0.0025% or 0.02%, or a vehicle (inactive) solution was used.

The primary outcome measured was change in terminal hair count within a defined target area, a standard but imperfect metric used in hair loss research. Registry results (NCT05802173) show mean hair-count gains of +20.3 and +22.4 in the active arms versus +14.0 on vehicle at 16 weeks; no statistical test has been posted or published, so it is not known whether the difference is significant. However, the duration of the study was short relative to the human hair growth cycle, which can span several months. This limits the ability to determine whether the observed changes represent true follicular recovery or temporary stimulation.

Importantly, these studies did not compare TDM-105795 directly against minoxidil or finasteride. Without head-to-head trials, it is impossible to determine whether TDM-105795 offers superior, equivalent, or inferior benefits. The absence of female participants and long-term follow-up further restricts the generalizability of the findings.

How TDM-105795 Differs in Practice, Not Just in Theory

In practice, the difference between TDM-105795 and established treatments lies less in demonstrated outcomes and more in unanswered questions. Minoxidil and finasteride have decades of efficacy data; for finasteride, how often side effects persist after stopping is still not known, and the US, UK and EU labels describe such reports. TDM-105795, by contrast, has 16 weeks of controlled data.

The claim of minimal systemic absorption comes from the sponsor's press release ("extremely low to no systemic exposure"); no thyroid-function results have been published. Small sample sizes and short exposure periods cannot rule out cumulative effects or rare adverse events. Additionally, the thyroid pathway itself raises specific concerns, as even subtle systemic thyroid modulation can have metabolic consequences if not tightly controlled.

From a scientific perspective, TDM-105795 represents an exploration of a new biological pathway rather than a proven alternative. Its potential value may ultimately lie in combination therapy, targeting aspects of hair loss biology not addressed by androgen suppression or vasodilation. At present, however, it remains an experimental compound whose differentiation is conceptual rather than conclusively clinical.

Critical Limitations and Unresolved Issues

Several limitations must be acknowledged when interpreting current data. The short duration of available trials prevents assessment of sustained efficacy. The reliance on surrogate endpoints such as hair counts does not fully capture cosmetic significance or patient-perceived improvement. Additionally, the lack of independent replication and peer-reviewed full trial publications limits transparency.

Animal and cellular studies provide useful mechanistic insights, but they cannot substitute for long-term human data. Hair follicle behavior in animal models does not perfectly mirror human androgenetic alopecia, particularly in the context of hormonal sensitivity.

What We Need to Know Moving Forward

From a critical standpoint, the most important unanswered questions are whether TDM-105795 can maintain benefits over years, whether it performs better or differently than existing therapies, and whether its thyroid-based mechanism introduces unique risks. Until large-scale, long-duration, peer-reviewed clinical trials are completed, TDM-105795 remains an investigational compound.

The difference between TDM-105795 and established hair loss ingredients is therefore not yet a difference of proven outcomes, but a difference of scientific direction. Whether that direction leads to meaningful clinical improvement remains an open question.

References

ClinicalTrials.gov. NCT05802173: A randomized, double-blind, vehicle-controlled, parallel group, multi-dose study to evaluate the efficacy and safety of TDM-105795 in male subjects with androgenetic alopecia (results posted 12 November 2025). https://clinicaltrials.gov/study/NCT05802173

Technoderma Medicines. (2024). Technoderma Medicines phase 2 clinical trial of TDM-105795 demonstrates hair growth in androgenetic alopecia [press release]. PR Newswire. https://www.prnewswire.com/news-releases/technoderma-medicines-phase-2-clinical-trial-of-tdm-105795-demonstrates-hair-growth-in-androgenetic-alopecia-302052631.html

Kim, J., Song, S. Y., & Sung, J. H. (2025). Recent advances in drug development for hair loss. International Journal of Molecular Sciences, 26(8), 3461. https://doi.org/10.3390/ijms26083461

Propecia (finasteride) US prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f904709-65aa-44ce-b144-b4c8a0416e36

MHRA Drug Safety Update (11 May 2026). Finasteride and dutasteride: updated safety warnings for psychiatric side effects and sexual dysfunction. https://www.gov.uk/drug-safety-update/finasteride-and-dutasteride-updated-safety-warnings-for-psychiatric-side-effects-and-sexual-dysfunction

Messenger, A. G., & Rundegren, J. (2004). Minoxidil: mechanisms of action on hair growth. British Journal of Dermatology, 150(2), 186–194. https://pubmed.ncbi.nlm.nih.gov/14996087

Paus, R., & Cotsarelis, G. (1999). The biology of hair follicles. New England Journal of Medicine, 341(7), 491–497. https://pubmed.ncbi.nlm.nih.gov/10441606/

van Beek, N., et al. (2008). Thyroid hormones directly alter human hair follicle functions. Journal of Clinical Endocrinology & Metabolism, 93(11), 4381–4388. https://pubmed.ncbi.nlm.nih.gov/18728176/